Acalisib (GS-9820)PI3Kδ inhibitor CAS# 870281-34-8 |
- Amyloid β-Protein (1-15)
Catalog No.:BCC1003
CAS No.:183745-81-5
- Beta-Amyloid (1-11)
Catalog No.:BCC1002
CAS No.:190436-05-6
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 870281-34-8 | SDF | Download SDF |
| PubChem ID | 11618268 | Appearance | Powder |
| Formula | C21H16FN7O | M.Wt | 401.4 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Synonyms | GS-9820; CAL-120 | ||
| Solubility | DMSO : 125 mg/mL (311.41 mM; Need ultrasonic) | ||
| Chemical Name | 6-fluoro-3-phenyl-2-[(1S)-1-(7H-purin-6-ylamino)ethyl]quinazolin-4-one | ||
| SMILES | CC(C1=NC2=C(C=C(C=C2)F)C(=O)N1C3=CC=CC=C3)NC4=NC=NC5=C4NC=N5 | ||
| Standard InChIKey | DOCINCLJNAXZQF-LBPRGKRZSA-N | ||
| Standard InChI | InChI=1S/C21H16FN7O/c1-12(27-19-17-18(24-10-23-17)25-11-26-19)20-28-16-8-7-13(22)9-15(16)21(30)29(20)14-5-3-2-4-6-14/h2-12H,1H3,(H2,23,24,25,26,27)/t12-/m0/s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Acalisib is a potent and selective PI3Kδ inhibitor with an IC50 of 12.7 nM.In Vitro:Acalisib (GS-9820) is more selective for PI3Kδ (IC50=12.7 nM) relative to other PI3K class I enzymes (IC50: PI3Kα, 5,441 nM; PI3Kβ, 3,377 nM; PI3Kγ, 1,389 nM). Acalisib is also 103-fold more selective against PI3Kδ than against related kinases, such as PI3KCIIβ (IC50>10 nM), hVPS34 (IC50=12.7 μM), DNA-PK (IC50=18.7 μM), and mTOR (IC50>10 nM). In fibroblasts, the PDGF receptor signals through PI3Kα and the GPCR for lysophosphatidic acid (LPA) signals through PI3Kβ. Acalisib reduces PDGF-induced pAkt by only 50% at 11,585 nM, and LPA-induced pAkt by 50% at 2,069 nM.In Vivo:To dissect the relative contribution of PI3Kα and PI3Kδ inhibition in the reduction of obesity, obese hyperphagic ob/ob mice are treated with a selective PI3Kα inhibitor, BYL-719, or with a selective PI3Kδ inhibitor, Acalisib (GS-9820). Remarkably, BYL-719 reduces body weight after 15 days of treatment to a similar extent as CNIO-PI3Ki, whereas Acalisib has no significant effect at the same doses as BYL-719. It should be noted that 10 mg/kg of Acalisib is sufficient to reduce the growth of multiple myeloma xenografts in mice[2]. References: | |||||
Kinase Assay
[1]
Biochemical in vitro lipid kinase assays are performed. A stock solution of Acalisib (GS-9820) is prepared in DMSO at a concentration of 10 mM. Ten-point kinase inhibitory activities are measured over a concentration range (5 to 104 nM) with ATP at a concentration consistent with the Km of each of the enzymes[1].
Cell Assay
[1]
The effect of inhibitors on RAW264.7 cell survival is evaluated using the MTT assay. RAW264.7 cells are seeded in Falcon flat bottom 96-well plates at a density of 2.5-3×104 cells/cm2 in 100 μL of DMEM with 10% FBS and 1% antibiotic solution. After seeding, the cells are allowed to attach for 24 h then exposed to control or Acalisib (GS-9820) (100 pM to 10 μM) for 24 h. After incubation at 37°C in 5% CO2, MTT substrate is added at a final concentration of 0.5 mg/mL for 4 h. Following a 4-h incubation, 100 μL of solubilization solution is added to each well to dissolve the formazan crystals and samples are analyzed after 24 h. Absorbance of the samples is assessed using a plate reader using a wavelength of 550 nm and a reference wavelength of 700 nm[1].
Animal Administration
[2]
Mice[2]
Ob/ob C57BL6J mice and Wild-type C57BL6J/Ola.Hsd mice are housed under specific pathogen free (SPF) conditions, at 22°C, and with 12 hours dark/light cycles (light cycle from 8 am to 8 pm). All mice used are males of 20 weeks of age. Mice are fed with standard chow diet (18% of fat-based caloric content). PI3K inhibitors are administered daily by oral gavage during 15 or 16 days as follows, BYL-719 (5 and 10 mg/kg) and Acalisib (5 and 10 mg/kg), CNIO-PI3Ki (1 and 5 mg/kg), dissolved in PEG-300 and 10% N-methyl-2-pyrrolidone.
References:
[1]. Shugg RP, et al. Effects of isoform-selective phosphatidylinositol 3-kinase inhibitors on osteoclasts: actions on cytoskeletal organization, survival, and resorption. J Biol Chem. 2013 Dec 6;288(49):35346-57.
[2]. Lopez-Guadamillas E, et al. PI3Kα inhibition reduces obesity in mice. Aging (Albany NY). 2016 Nov 4;8(11):2747-2753.
Acalisib (GS-9820) Dilution Calculator
Acalisib (GS-9820) Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.4913 mL | 12.4564 mL | 24.9128 mL | 49.8256 mL | 62.282 mL |
| 5 mM | 0.4983 mL | 2.4913 mL | 4.9826 mL | 9.9651 mL | 12.4564 mL |
| 10 mM | 0.2491 mL | 1.2456 mL | 2.4913 mL | 4.9826 mL | 6.2282 mL |
| 50 mM | 0.0498 mL | 0.2491 mL | 0.4983 mL | 0.9965 mL | 1.2456 mL |
| 100 mM | 0.0249 mL | 0.1246 mL | 0.2491 mL | 0.4983 mL | 0.6228 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Acalisib (GS-9820) is a potent and selective inhibitor of PI3Kδ with IC50 value of 12.7 nM [1].
Phosphoinositide 3-kinases (PI3Ks) are a family of lipid kinases that phosphorylating the 3’-hydroxyl group of phosphatidylinositol-4,5-bisphosphate (PIP2) to produce phosphatidylinositol-3,4,5-trisphosphate (PIP3). PI3Ks plays important roles in cell proliferation, survival, differentiation and metabolism. PI3Kδ plays an important role in inflammation, immune function, cell migration and vesicle trafficking, and is highly expressed in cells of hematopoietic origin [1].
Acalisib (GS-9820) is a potent and selective PI3Kδ inhibitor. GS-9820 inhibited PI3Kα, β, γ and δ with IC50 values of 5441, 3377, 1389 and 12.7 nM, respectively. In fibroblasts, GS-9820 inhibited PDGF- and LPA-induced pAkt with IC50 values of 11,585 and 2,069 nM respectively, which were through PI3Kα and PI3Kβ. In basophils, GS-9820 inhibited FcεRI PI3Kδ- and fMLP PI3Kγ-mediated CD63 expression with EC50 values of 14 nM and 2,065 nM, respectively. In isolated rat osteoclasts, GS-9820 induced prompt retraction of lamellipodia by 65-75% within 10-15 min. GS-9820 also significantly reduced the incidence of F-actin belts and inhibited osteoclast survival stimulated by RANKL [1].
Reference:
[1]. Shugg RP, Thomson A, Tanabe N, et al. Effects of isoform-selective phosphatidylinositol 3-kinase inhibitors on osteoclasts: actions on cytoskeletal organization, survival, and resorption. J Biol Chem, 2013, 288(49): 35346-35357.
- Apilimod mesylate
Catalog No.:BCC5287
CAS No.:870087-36-8
- Tozadenant
Catalog No.:BCC2011
CAS No.:870070-55-6
- A 839977
Catalog No.:BCC4290
CAS No.:870061-27-1
- xylitol pentacetate
Catalog No.:BCN6267
CAS No.:13437-68-8
- Inositol
Catalog No.:BCN8471
CAS No.:87-89-8
- D-Mannitol busulfan
Catalog No.:BCN3789
CAS No.:1187-00-4
- Tartaric acid
Catalog No.:BCN3824
CAS No.:87-69-4
- Pyrogallol
Catalog No.:BCN4424
CAS No.:87-66-1
- Gramine
Catalog No.:BCN4959
CAS No.:87-52-5
- trans-Caryophyllene
Catalog No.:BCN2644
CAS No.:87-44-5
- Isosorbide dinitrate
Catalog No.:BCC9004
CAS No.:87-33-2
- Ac-DL-Trp-OH
Catalog No.:BCC3119
CAS No.:87-32-1
- CAL-101 (Idelalisib, GS-1101)
Catalog No.:BCC1270
CAS No.:870281-82-6
- 3,23-Dioxo-9,19-cyclolanost-24-en-26-oic acid
Catalog No.:BCN1322
CAS No.:870456-88-5
- Bis-5,5-nortrachelogenin
Catalog No.:BCN6516
CAS No.:870480-56-1
- GW2580
Catalog No.:BCC1096
CAS No.:870483-87-7
- Ritanserin
Catalog No.:BCC7214
CAS No.:87051-43-2
- Zeylasteral
Catalog No.:BCN3065
CAS No.:87064-16-2
- Euphohelioscopin A
Catalog No.:BCN6501
CAS No.:87064-61-7
- PAP-1
Catalog No.:BCC1836
CAS No.:870653-45-5
- AC 261066
Catalog No.:BCC7848
CAS No.:870773-76-5
- Leptomycin B
Catalog No.:BCC7223
CAS No.:87081-35-4
- MK 0893
Catalog No.:BCC1752
CAS No.:870823-12-4
- E 2012
Catalog No.:BCC1540
CAS No.:870843-42-8
